Literature DB >> 17158757

Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach.

S Tozlu1, I Girault, S Vacher, J Vendrell, C Andrieu, F Spyratos, P Cohen, R Lidereau, I Bieche.   

Abstract

The estrogen receptor alpha (ERalpha) plays a critical role in the pathogenesis and clinical behavior of breast cancer. To obtain further insights into the molecular basis of estrogen-dependent forms of this malignancy, we used real-time quantitative reverse transcription (RT)-PCR to compare the mRNA expression of 560 selected genes in ERalpha-positive and ERalpha-negative breast tumors. Fifty-one (9.1%) of the 560 genes were significantly upregulated in ERalpha-positive breast tumors compared with ERalpha-negative breast tumors. In addition to well-known ERalpha-induced genes (PGR, TFF1/PS2, BCL2, ERBB4, CCND1, etc.) and genes recently identified by cDNA microarray-based approaches (GATA3, TFF3, MYB, STC2, HPN/HEPSIN, FOXA1, XBP1, SLC39A6/LIV-1, etc.), an appreciable number of novel genes were identified, many of, which were weakly expressed. This validates the use of large-scale real-time RT-PCR as a method complementary to cDNA microarrays for molecular tumor profiling. Most of the new genes identified here encoded secreted proteins (SEMA3B and CLU), growth factors (BDNF, FGF2 and EGF), growth factor receptors (IL6ST, PTPRT, RET, VEGFR1 and FGFR2) or metabolic enzymes (CYP2B6, CA12, ACADSB, NAT1, LRBA, SLC7A2 and SULT2B1). Importantly, we also identified a large number of genes encoding proteins with either pro-apoptotic (PUMA, NOXA and TATP73) or anti-apoptotic properties (BCL2, DNTP73 and TRAILR3). Surprisingly, only a small proportion of the 51 genes identified in breast tumor biopsy specimens were confirmed to be ERalpha-regulated and/or E2-regulated in vitro (cultured cell lines). Therefore, this study identified a limited number of genes and signaling pathways, which better delineate the role of ERalpha in breast cancer. Some of the genes identified here could be useful for diagnosis or for predicting endocrine responsiveness, and could form the basis for novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17158757     DOI: 10.1677/erc.1.01120

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  102 in total

1.  NF-κB signaling is required for XBP1 (unspliced and spliced)-mediated effects on antiestrogen responsiveness and cell fate decisions in breast cancer.

Authors:  Rong Hu; Anni Warri; Lu Jin; Alan Zwart; Rebecca B Riggins; Hong-Bin Fang; Robert Clarke
Journal:  Mol Cell Biol       Date:  2014-11-03       Impact factor: 4.272

Review 2.  The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer.

Authors:  Kathryn M Taylor; Helen E Morgan; Kathryn Smart; Normawati M Zahari; Sara Pumford; Ian O Ellis; John F R Robertson; Robert I Nicholson
Journal:  Mol Med       Date:  2007 Jul-Aug       Impact factor: 6.354

3.  Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer.

Authors:  Karen S Anderson; Sahar Sibani; Garrick Wallstrom; Ji Qiu; Eliseo A Mendoza; Jacob Raphael; Eugenie Hainsworth; Wagner R Montor; Jessica Wong; Jin G Park; Naa Lokko; Tanya Logvinenko; Niroshan Ramachandran; Andrew K Godwin; Jeffrey Marks; Paul Engstrom; Joshua Labaer
Journal:  J Proteome Res       Date:  2010-11-23       Impact factor: 4.466

4.  Differential dependency network analysis to identify condition-specific topological changes in biological networks.

Authors:  Bai Zhang; Huai Li; Rebecca B Riggins; Ming Zhan; Jianhua Xuan; Zhen Zhang; Eric P Hoffman; Robert Clarke; Yue Wang
Journal:  Bioinformatics       Date:  2008-12-26       Impact factor: 6.937

5.  Detection of early prostate cancer using a hepsin-targeted imaging agent.

Authors:  Kimberly A Kelly; Sunita R Setlur; Robert Ross; Rajesh Anbazhagan; Peter Waterman; Mark A Rubin; Ralph Weissleder
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

Review 6.  HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.

Authors:  Frank E Jones
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-13       Impact factor: 2.673

7.  Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification.

Authors:  Yuzhi Yin; Hongyan Yuan; Xiao Zeng; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

8.  Chromatin context dominates estrogen regulation of pS2 gene expression.

Authors:  Akua K Oduro; Michael K Fritsch; Fern E Murdoch
Journal:  Exp Cell Res       Date:  2008-07-15       Impact factor: 3.905

Review 9.  The role of X-box binding protein-1 in tumorigenicity.

Authors:  Ayesha N Shajahan; Rebecca B Riggins; Robert Clarke
Journal:  Drug News Perspect       Date:  2009-06

10.  Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells.

Authors:  Robert Clarke; Ayesha N Shajahan; Rebecca B Riggins; Younsook Cho; Anatasha Crawford; Jianhua Xuan; Yue Wang; Alan Zwart; Ruchi Nehra; Minetta C Liu
Journal:  J Steroid Biochem Mol Biol       Date:  2009-03       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.